23 completed, 23 unknown, 13 recruiting, 10 not yet recruiting. 45 Phase 2, 26 Phase 1, 10 Phase 3.
Follow fluzoparib: new trials by email Literature Review of fluzoparib trials Research Report on fluzoparib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco) Fluzoparib, Physician choice - Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 334 | 2026-03-31 | 2026-01-20 |
| Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer Fluzoparib - Ovarian Cancer | Phase 2 | Not yet recruiting | Jinhua Zhou | 43 | 2026-02-28 | 2026-02-03 |
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-12-31 | 2025-08-26 |
| A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed Glioblastoma Fluzoparib with Temozolomide - Glioblastoma | Phase 2 | Not yet recruiting | Tongji Hospital | 30 | 2025-07-10 | 2025-07-02 |
| Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma irinotecan liposome (II) + temozolomide + fluzoparib - Ewing Sarcoma | Phase 2 | Recruiting | Sun Yat-sen University | 29 | 2025-04-15 | 2025-05-31 |
| Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer Fluzoparib Capsules, Apatinib Mesylate Tablets - Ovarian Cancer | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Xiamen University | 37 | 2024-12-01 | 2024-01-03 |
| Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC Intensity-modulated radiation therapy (IMRT) in combination with fluzoparib, abiraterone acetate tablets (II), and prednisone. - Metastatic Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Jianbin Bi | 40 | 2024-11-27 | 2025-05-14 |
| Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer Fluzoparib, Bevacizumab, Paclitaxel - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Qilu Hospital of Shandong University | 105 | 2024-11-27 | 2024-12-16 |
| Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer Fluzoparib, Apatinib Mesylate - Epithelial Ovarian Cancer, Efficacy | Phase 3 | Unknown | Anhui Provincial Hospital | 51 | 2024-10-01 | 2024-08-06 |
| Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer Fluzoparib, Dalpiciclib - Ovarian Cancer | Phase 2 | Not yet recruiting | Fudan University | 30 | 2024-09-01 | 2024-08-14 |
| PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer Fluzoparib, Dalpiciclib, Fulvestrant/AI - Breast Cancer Metastatic | Phase 3 | Active not recruiting | Zhimin Shao | 307 | 2024-09-01 | 2024-09-25 |
| Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping Fluzoparib, Everolimus, Fulvestrant - Breast Cancer | Phase 2 | Unknown | Fudan University | 260 | 2024-08-21 | 2024-08-19 |
| Fluzoparib Neoadjuvant Therapy for Ovarian Cancer Fluzoparib - Ovarian Cancer | Phase 2 | Unknown | Qilu Hospital of Shandong University | 48 | 2024-06-18 | 2024-11-27 |
| Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer Fluzoparib, Apatinib Mesylate, Capecitabine tablets - Fludzoparib" and Anti-angiogenic, HRD-positive/HER2-negative Advanced Breast Cancer | Phase 3 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 200 | 2024-06-12 | 2025-08-15 |
| Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian Cancer Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib - Platinum-sensitive Relapsed Ovarian Cancer | Phase 2 | Not yet recruiting | The First Hospital of Jilin University | 22 | 2024-06-01 | 2024-06-06 |
| Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer Fluzoparib, Camrelizumab, paclitaxel (albumin bound) - Endometrial Carcinoma, TP53 Mutation | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 117 | 2024-05-10 | 2024-05-14 |
| Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer Adebrelimab plus Fluzoparib - Female Breast Cancer Patients, Histopathologically Confirmed Advanced HR +/HER2-invasive Breast Cancer | Phase 2 | Not yet recruiting | Zhejiang Cancer Hospital | 40 | 2024-04-16 | 2024-02-12 |
| A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors JS105, Fulvestrant injection, Dalpiciclib Isetionate Tablets - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Risen (Suzhou) Pharma Tech Co., Ltd. | 306 | 2024-01-11 | 2025-07-25 |
| Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi Fluzoparib, Fluzoparib+Apatinib - Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary | Phase 2 | Unknown | Guangxi Medical University | 80 | 2023-12-10 | 2023-12-07 |
| A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm)) - PARP Inhibitor for Esophageal Squamous Cell Carcinoma | Phase 2 | Unknown | Chongqing University Cancer Hospital | 120 | 2023-11-01 | 2023-09-26 |
Showing 20 of 75. Sign in to see all of them.
Ovarian Neoplasms (17) · Breast Neoplasms (6) · Triple Negative Breast Neoplasms (5) · Fallopian Tube Neoplasms (4) · Prostatic Neoplasms (4) · Neoplasms (3) · Sarcoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasm Metastasis (2) · Pancreatic Neoplasms (2) · Recurrence (2) · Small Cell Lung Carcinoma (2) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1)
Jiangsu HengRui Medicine Co., Ltd. (26) · Fudan University (13) · Atridia Pty Ltd. (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Sun Yat-sen University (3) · Qilu Hospital of Shandong University (2) · Anhui Provincial Hospital (1) · Chongqing University Cancer Hospital (1) · Fujun Zhang (1) · Guangxi Medical University (1) · Huazhong University of Science and Technology (1) · Jianbin Bi (1) · Jin Li (1) · Jinhua Zhou (1) · Risen (Suzhou) Pharma Tech Co., Ltd. (1)
China (59) · Australia (4) · France (2) · Belgium (1) · Czechia (1) · Hungary (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1) · United States (1)
Beihua Kong (1) · Boyong Shen, M.D. (1) · Chaosu Hu, M.D. (1) · Fujun Zhang, Ph.D,M.D (1) · Guoping Yang, PhD (1) · Haitao Wang (1) · Haiyan Liu (1) · Hongqian Guo, Phd (1) · Huiping Li, PhD (1) · Jianbin Bi, Doctor (1) · Jianli Zhao (1) · Jin Wang, MD (1) · Jing Wang, Ph.D. (1) · Junxiang Wen, PhD, MD (1)
PMID 32719455, PMID 33420642, PMID 33570247, PMID 35105939, PMID 35404684, PMID 36184642, PMID 37185961, PMID 37775744, PMID 38290515, PMID 38362377, PMID 39232761, PMID 41308673